Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 5.55B | 7.21B | 6.59B | 6.06B | 4.93B | 5.34B |
Gross Profit | 2.20B | 2.79B | 2.32B | 2.23B | 1.96B | 2.26B |
EBITDA | 1.17B | 1.48B | 1.18B | 1.16B | 922.47M | 1.37B |
Net Income | 180.38M | 156.92M | 59.31M | 208.28M | 265.33M | 618.55M |
Balance Sheet | ||||||
Total Assets | 20.98B | 21.41B | 21.44B | 21.53B | 19.23B | 15.27B |
Cash, Cash Equivalents and Short-Term Investments | 1.01B | 1.00B | 544.50M | 591.24M | 2.68B | 590.51M |
Total Debt | 10.05B | 10.09B | 10.12B | 9.75B | 9.32B | 6.91B |
Total Liabilities | 12.68B | 12.80B | 13.47B | 13.08B | 11.09B | 8.55B |
Stockholders Equity | 5.64B | 5.88B | 5.83B | 6.13B | 6.10B | 5.11B |
Cash Flow | ||||||
Free Cash Flow | 673.55M | 530.80M | -87.14M | -386.43M | 281.89M | 747.78M |
Operating Cash Flow | 949.70M | 902.17M | 208.28M | -10.87M | 596.98M | 1.11B |
Investing Cash Flow | -572.05M | 886.67M | -397.64M | -1.98B | -29.39M | -858.12M |
Financing Cash Flow | -1.72B | -1.36B | 186.04M | -173.49M | 1.47B | -354.40M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
78 Outperform | $80.32B | 18.34 | 18.84% | 4.13% | 3.46% | -13.29% | |
72 Outperform | $111.94B | 11.32 | 7.17% | 4.86% | -9.32% | 120.62% | |
69 Neutral | $146.96B | 22.33 | 89.11% | 3.44% | 13.10% | 110.67% | |
68 Neutral | $89.80B | 17.80 | 28.96% | 5.58% | 2.57% | ― | |
68 Neutral | $139.09B | 22.30 | 32.08% | 2.80% | 3.69% | 501.26% | |
63 Neutral | $8.51B | 20.48 | 5.41% | 1.45% | 10.05% | 98.22% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
On July 29, 2025, Grifols announced its half-year financial results for 2025, showcasing a 7% increase in revenues to EUR 3,677 million and a nearly fourfold rise in net profit to EUR 177 million, driven by strong performance in its Biopharma segment. The company also reduced its leverage ratio and reinstated a dividend payment, reflecting its commitment to shareholder returns. Grifols plans to launch Fibrinogen in Europe and the U.S. following FDA approval, and it has completed the delisting of Biotest from the Frankfurt Stock Exchange, increasing its equity stake to 80.32%. The company remains focused on its Value Creation Plan, leveraging its business model to mitigate potential impacts from trade tariffs.
On July 28, 2025, Grifols, S.A.’s Board of Directors approved an interim dividend payment of €0.15 per share for the 2025 profit. The payment will be distributed on August 13, 2025, with a total dividend amounting to €102,076,365.60. This decision reflects Grifols’ commitment to providing value to its shareholders and may impact investor sentiment positively.
On July 28, 2025, Grifols, S.A.’s Board of Directors resolved to amend its internal regulations, renaming the Sustainability Committee to the ‘Sustainability, Communication and Reputation Committee.’ This change expands the committee’s authority to include the supervision of the company’s corporate reputation. The updated regulations will be communicated to the National Securities Market Commission and filed with the Commercial Registry of Barcelona, with further details to be shared at the next General Shareholders’ Meeting.